Related Experiment Video
Updated: Oct 29, 2025

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions1
Jack C de la Torre1,2, Francisco Gonzalez-Lima3
1Professor of Neuropsychology (Adjunct), Department of Psychology, University of Texas at Austin, Austin, TX, USA.
No abstract available in PubMed .
More Related Videos
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
06:40Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
Published on: January 25, 2018
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinical Trials: Overview
FDA Approved Drugs: Changes to Approved Drugs
Drug Regulation